LYXUMIA (lixisenatide), antidiabetic

DIABETOLOGY - New medicinal product

Opinions on drugs - Posted on Sep 27 2016

Inclusion

LYXUMIA is a GLP-1 agonist that has Marketing Authorisation in the treatment of adult type 2 diabetes to obtain glycaemic control in combination with oral antidiabetics and/or basal insulin, when these, combined with diet and exercise, do not provide adequate glycaemic control.
The size effect of LYXUMIA in terms of glycaemic control is modest. Other GLP-1 analogues have established efficacy in terms of glycaemic control.
LYXUMIA is not superior to placebo in terms of reducing cardiovascular events.

Insufficient

Therapeutic use

Évaluation des médicaments

All our publications

My account